Clinical Trial: A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675954) titled 'A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis' on June 17.

Brief Summary: This is a phase 3, open-label, randomized clinical trial in adults and adolescents aged 15 years or older who need treatment for rifampicin-resistant tuberculosis in South Africa.

The goal of this clinical trial is to learn whether a 6-month MDR-END Plus regimen works as well as current standard of care (SoC) treatment for rifampicin-resistant tuberculosis. The trial will also learn whether the MDR-END Plus regimen is safer and easier to tolerate than SoC regimens.

The main questions this trial aims to answer are:

* Does the MDR-END Pl...